AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (871.9 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Impact of pre-neoadjuvant radioactive iodine seed marking on pathologic complete response and survival in early-stage breast cancer patients

Yihao Geng1,*Qi Zhang1,*Zhao Bi1,*Zhiqiang Shi1Qiuchen Zhao2Xiaowei Qi3Rongrong Zhao1 ( )Yongsheng Wang1 ( )Pengfei Qiu1 ( )
Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
Cancer Research UK Cambridge Centre and Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK
Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

*These authors contributed equally to this work.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-23-1-78_ESM.pdf (378.4 KB)

References

【1】
【1】
 
 
Cancer Biology & Medicine
Pages 78-85

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Geng Y, Zhang Q, Bi Z, et al. Impact of pre-neoadjuvant radioactive iodine seed marking on pathologic complete response and survival in early-stage breast cancer patients. Cancer Biology & Medicine, 2026, 23(1): 78-85. https://doi.org/10.20892/j.issn.2095-3941.2025.0578

303

Views

16

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 23 September 2025
Accepted: 19 November 2025
Published: 26 December 2025
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)